Human aquaporin-4 and molecular modeling: Historical perspective and view to the future

International Journal of Molecular Sciences

Volumn 17, Issue 7, 2016, Pages

  Mangiatordi, Giuseppe Felice ^a   Alberga, Domenico ^b   Trisciuzzi, Daniela ^a   Lattanzi, Gianluca ^c   Nicolotti, Orazio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b PSL RESEARCH UNIVERSITY   (France)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Druggability; Epitope; Gating mechanisms; Human aquaporin 4 (hAQP4); Molecular dynamic (MD) simulations; Neuromyelitis optica (NMO) IgG binding

Indexed keywords

2 (NICOTINAMIDO) 1,3,4 THIADIAZOLE; ACETAZOLAMIDE; AQUAPORIN 4; ARBIDOL; BERBAMINE; FLAVONOID; RIZATRIPTAN; SUMATRIPTAN; TAMARIXETIN; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G;

BRAIN EDEMA; CRYSTAL STRUCTURE; GENE MUTATION; HUMAN; MYELOOPTIC NEUROPATHY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SUPRAMOLECULAR CHEMISTRY; WATER PERMEABILITY; X RAY CRYSTALLOGRAPHY; CHEMISTRY; HISTORY; METABOLISM; MOLECULAR MODEL; PATHOLOGY; PROTEIN CONFORMATION;

AQUAPORIN 4; HISTORY, 21ST CENTURY; HUMANS; IMMUNOGLOBULIN G; MODELS, MOLECULAR; NEUROMYELITIS OPTICA; PROTEIN CONFORMATION;

EID: 84978540231     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17071119     Document Type: Review

References (124)

1. Nielsen, S.; Nagelhus, E. A.; Amiry-Moghaddam, M.; Bourque, C.; Agre, P.; Ottersen, O. P. Specialized membrane domains for water transport in glial cells: High-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J. Neurosci. Off. J. Soc. Neurosci. 1997, 17, 171-180.
2. Borgnia, M.; Nielsen, S.; Engel, A.; Agre, P. Cellular and molecular biology of the aquaporin water channels. Annu. Rev. Biochem. 1999, 68, 425-458. [CrossRef] [PubMed].
3. Sui, H.; Han, B. G.; Lee, J. K.; Walian, P.; Jap, B. K. Structural basis of water-specific transport through the AQP1 water channel. Nature 2001, 414, 872-878. [CrossRef] [PubMed].
4. Sachdeva, R.; Singh, B. Insights into structural mechanisms of gating induced regulation of aquaporins. Prog. Biophys. Mol. Biol. 2014, 114, 69-79. [CrossRef] [PubMed].
5. Ilan, B.; Tajkhorshid, E.; Schulten, K.; Voth, G. A. The mechanism of proton exclusion in aquaporin channels. Proteins 2004, 55, 223-228. [CrossRef] [PubMed].
6. Li, H.; Chen, H.; Steinbronn, C.; Wu, B.; Beitz, E.; Zeuthen, T.; Voth, G. A. Enhancement of proton conductance by mutations of the selectivity filter of aquaporin-1. J. Mol. Biol. 2011, 407, 607-620. [CrossRef] [PubMed].
7. Hub, J. S.; de Groot, B. L. Mechanism of selectivity in aquaporins and aquaglyceroporins. Proc. Natl. Acad. Sci. USA 2008, 105, 1198-1203. [CrossRef] [PubMed].
8. Zeidel, M. L.; Ambudkar, S. V.; Smith, B. L.; Agre, P. Reconstitution of functional water channels in liposomes containing purified red cell CHIP28 protein. Biochemistry 1992, 31, 7436-7440. [CrossRef] [PubMed].
9. Agre, P.; King, L. S.; Yasui, M.; Guggino, W. B.; Ottersen, O. P.; Fujiyoshi, Y.; Engel, A.; Nielsen, S. Aquaporin water channels-From atomic structure to clinical medicine. J. Physiol. 2002, 542, 3-16. [CrossRef] [PubMed].
10. Day, R. E.; Kitchen, P.; Owen, D. S.; Bland, C.; Marshall, L.; Conner, A. C.; Bill, R. M.; Conner, M. T. Human aquaporins: Regulators of transcellular water flow. Biochim. Biophys. Acta 2014, 1840, 1492-1506. [CrossRef] [PubMed].
11. Schrier, R. W. Aquaporin-related disorders of water homeostasis. Drug News Perspect. 2007, 20, 447-453. [CrossRef] [PubMed].
12. Agre, P.; Kozono, D. Aquaporin water channels: Molecular mechanisms for human diseases 1. FEBS Lett. 2003, 555, 72-78. [CrossRef].
13. Lennon, V. A.; Kryzer, T. J.; Pittock, S. J.; Verkman, A. S.; Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 2005, 202, 473-477. [CrossRef] [PubMed].
14. Castle, N. A. Aquaporins as targets for drug discovery. Drug Discov. Today 2005, 10, 485-493. [CrossRef].
15. De Groot, B. L.; Frigato, T.; Helms, V.; Grubmüller, H. The mechanism of proton exclusion in the aquaporin-1 water channel. J. Mol. Biol. 2003, 333, 279-293. [CrossRef] [PubMed].
16. Hub, J. S.; Grubmüller, H.; de Groot, B. L. Dynamics and energetics of permeation through aquaporins. What do we learn from molecular dynamics simulations? Handb. Exp. Pharmacol. 2009, 190, 57-76.
17. Hub, J. S.; Aponte-Santamaría, C.; Grubmüller, H.; de Groot, B. L. Voltage-regulated water flux through aquaporin channels in silico. Biophys. J. 2010, 99, L97-L99. [CrossRef] [PubMed].
18. Aponte-Santamaría, C.; Briones, R.; Schenk, A. D.; Walz, T.; de Groot, B. L. Molecular driving forces defining lipid positions around aquaporin-0. Proc. Natl. Acad. Sci. USA 2012, 109, 9887-9892. [CrossRef] [PubMed].
19. Seeliger, D.; Zapater, C.; Krenc, D.; Haddoub, R.; Flitsch, S.; Beitz, E.; Cerdà, J.; de Groot, B. L. Discovery of novel human aquaporin-1 blockers. ACS Chem. Biol. 2013, 8, 249-256. [CrossRef] [PubMed].
20. Assentoft, M.; Kaptan, S.; Fenton, R. A.; Hua, S. Z.; de Groot, B. L.; MacAulay, N. Phosphorylation of rat aquaporin-4 at Ser111 is not required for channel gating. Glia 2013, 61, 1101-1112. [CrossRef] [PubMed].
21. Ho, J. D.; Yeh, R.; Sandstrom, A.; Chorny, I.; Harries, W. E. C.; Robbins, R. A.; Miercke, L. J. W.; Stroud, R. M. Crystal structure of human aquaporin 4 at 1. 8 A and its mechanism of conductance. Proc. Natl. Acad. Sci. USA 2009, 106, 7437-7442. [CrossRef] [PubMed].
22. Alberga, D.; Nicolotti, O.; Lattanzi, G.; Nicchia, G. P.; Frigeri, A.; Pisani, F.; Benfenati, V.; Mangiatordi, G. F. A new gating site in human aquaporin-4: Insights from molecular dynamics simulations. Biochim. Biophys. Acta 2014, 1838, 3052-3060. [CrossRef] [PubMed].
23. Umenishi, F.; Verkman, A. S. Isolation and functional analysis of alternative promoters in the human aquaporin-4 water channel gene. Genomics 1998, 50, 373-377. [CrossRef] [PubMed].
24. Yang, B.; Ma, T.; Verkman, A. S. cDNA cloning, gene organization, and chromosomal localization of a human mercurial insensitive water channel. J. Biol. Chem. 1995, 270, 22907-22913. [CrossRef] [PubMed].
25. Amiry-Moghaddam, M.; Ottersen, O. P. The molecular basis of water transport in the brain. Nat. Rev. Neurosci. 2003, 4, 991-1001. [CrossRef] [PubMed].
26. Yoneda, K.; Yamamoto, N.; Asai, K.; Sobue, K.; Fujita, Y.; Fujita, M.; Mase, M.; Yamada, K.; Nakanishi, M.; Tada, T.; et al. Regulation of aquaporin-4 expression in astrocytes. Brain Res. Mol. Brain Res. 2001, 89, 94-102. [CrossRef].
27. Nicchia, G. P.; Ficarella, R.; Rossi, A.; Giangreco, I.; Nicolotti, O.; Carotti, A.; Pisani, F.; Estivill, X.; Gasparini, P.; Svelto, M.; et al. D184E mutation in aquaporin-4 gene impairs water permeability and links to deafness. Neuroscience 2011, 197, 80-88. [CrossRef] [PubMed].
28. Li, J.; Verkman, A. S. Impaired hearing in mice lacking aquaporin-4 water channels. J. Biol. Chem. 2001, 276, 31233-31237. [CrossRef] [PubMed].
29. Zador, Z.; Stiver, S.; Wang, V.; Manley, G. T. Role of aquaporin-4 in cerebral edema and stroke. Handb. Exp. Pharmacol. 2009, 190, 159-170. [PubMed].
30. Papadopoulos, M. C.; Verkman, A. S. Aquaporin-4 and brain edema. Pediatr. Nephrol. Berl. Ger. 2007, 22, 778-784. [CrossRef] [PubMed].
31. Heuser, K.; Nagelhus, E. A.; Taubøll, E.; Indahl, U.; Berg, P. R.; Lien, S.; Nakken, S.; Gjerstad, L.; Ottersen, O. P. Variants of the genes encoding AQP4 and Kir4. 1 are associated with subgroups of patients with temporal lobe epilepsy. Epilepsy Res. 2010, 88, 55-64. [CrossRef] [PubMed].
32. Alexander, J. J.; Bao, L.; Jacob, A.; Kraus, D. M.; Holers, V. M.; Quigg, R. J. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 2003, 1639, 169-176. [CrossRef] [PubMed].
33. Krampla, W.; Aboul-Enein, F.; Jecel, J.; Lang, W.; Fertl, E.; Hruby, W.; Kristoferitsch, W. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur. Radiol. 2009, 19, 2535-2543. [CrossRef] [PubMed].
34. Huber, V. J.; Tsujita, M.; Yamazaki, M.; Sakimura, K.; Nakada, T. Identification of arylsulfonamides as Aquaporin 4 inhibitors. Bioorg. Med. Chem. Lett. 2007, 17, 1270-1273. [CrossRef] [PubMed].
35. Tanimura, Y.; Hiroaki, Y.; Fujiyoshi, Y. Acetazolamide reversibly inhibits water conduction by aquaporin-4. J. Struct. Biol. 2009, 166, 16-21. [CrossRef] [PubMed].
36. Igarashi, H.; Huber, V. J.; Tsujita, M.; Nakada, T. Pretreatment with a novel aquaporin 4 inhibitor, TGN-020, significantly reduces ischemic cerebral edema. Neurol. Sci. 2011, 32, 113-116. [CrossRef] [PubMed].
37. Huber, V. J.; Tsujita, M.; Nakada, T. Identification of aquaporin 4 inhibitors using in vitro and in silico methods. Bioorg. Med. Chem. 2009, 17, 411-417. [CrossRef] [PubMed].
38. Tradtrantip, L.; Zhang, H.; Anderson, M. O.; Saadoun, S.; Phuan, P.-W.; Papadopoulos, M. C.; Bennett, J. L.; Verkman, A. S. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 2012, 26, 2197-2208. [CrossRef] [PubMed].
39. Papadopoulos, M. C.; Bennett, J. L.; Verkman, A. S. Treatment of neuromyelitis optica: State-of-the-art and emerging therapies. Nat. Rev. Neurol. 2014, 10, 493-506. [CrossRef] [PubMed].
40. Agmon, N. The Grotthuss mechanism. Chem. Phys. Lett. 1995, 244, 456-462. [CrossRef].
41. Carbrey, J. M.; Agre, P. Discovery of the aquaporins and development of the field. In Handbook of Experimental Pharmacology; Beitz, P. D. E., Ed.; Springer: Berlin/Heidelberg, Germany, 2009; Volume 190, pp. 3-28.
42. Verkman, A. S.; Mitra, A. K. Structure and function of aquaporin water channels. Am. J. Physiol. 2000, 278, F13-F28.
43. De Groot, B. L.; Engel, A.; Grubmüller, H. A refined structure of human aquaporin-1. FEBS Lett. 2001, 504, 206-211. [CrossRef].
44. De Groot, B. L.; Grubmüller, H. Water permeation across biological membranes: Mechanism and dynamics of aquaporin-1 and GlpF. Science 2001, 294, 2353-2357. [CrossRef] [PubMed].
45. Tajkhorshid, E.; Nollert, P.; Jensen, M. Ø.; Miercke, L. J. W.; O'Connell, J.; Stroud, R. M.; Schulten, K. Control of the selectivity of the aquaporin water channel family by global orientational tuning. Science 2002, 296, 525-530. [CrossRef] [PubMed].
46. Chakrabarti, N.; Roux, B.; Pomès, R. Structural determinants of proton blockage in aquaporins. J. Mol. Biol. 2004, 343, 493-510. [CrossRef] [PubMed].
47. Chen, H.; Wu, Y.; Voth, G. A. Origins of proton transport behavior from selectivity domain mutations of the aquaporin-1 channel. Biophys. J. 2006, 90, L73-L75. [CrossRef] [PubMed].
48. Kreida, S.; Törnroth-Horsefield, S. Structural insights into aquaporin selectivity and regulation. Curr. Opin. Struct. Biol. 2015, 33, 126-134. [CrossRef] [PubMed].
49. Kosinska Eriksson, U.; Fischer, G.; Friemann, R.; Enkavi, G.; Tajkhorshid, E.; Neutze, R. Subangstrom resolution X-ray structure details aquaporin-water interactions. Science 2013, 340, 1346-1349. [CrossRef] [PubMed].
50. Beitz, E.; Wu, B.; Holm, L. M.; Schultz, J. E.; Zeuthen, T. Point mutations in the aromatic/arginine region in aquaporin 1 allow passage of urea, glycerol, ammonia, and protons. Proc. Natl. Acad. Sci. USA 2006, 103, 269-274. [CrossRef] [PubMed].
51. Smart, O. S.; Goodfellow, J. M.; Wallace, B. A. The pore dimensions of gramicidin A. Biophys. J. 1993, 65, 2455-2460. [CrossRef].
52. Cui, Y.; Bastien, D. A. Water transport in human aquaporin-4: Molecular dynamics (MD) simulations. Biochem. Biophys. Res. Commun. 2011, 412, 654-659. [CrossRef] [PubMed].
53. Izrailev, S.; Stepaniants, S.; Isralewitz, B.; Kosztin, D.; Lu, H.; Molnar, F.; Wriggers, W.; Schulten, K. Steered molecular dynamics. In Computational Molecular Dynamics: Challenges, Methods, Ideas; Deuflhard, P., Hermans, J., Leimkuhler, B., Mark, A. E., Reich, S., Skeel, R. D., Eds.; Springer: Berlin/Heidelberg, Germany, 1999; pp. 39-65.
54. Bossis, G.; Quentrec, B.; Boon, J. P. Brownian dynamics and the fluctuation-dissipation theorem. Mol. Phys. 1982, 45, 191-196. [CrossRef].
55. Kutzner, C.; Grubmüller, H.; de Groot, B. L.; Zachariae, U. Computational electrophysiology: the molecular dynamics of ion channel permeation and selectivity in atomistic detail. Biophys. J. 2011, 101, 809-817. [CrossRef] [PubMed].
56. Németh-Cahalan, K. L.; Kalman, K.; Hall, J. E. Molecular basis of pH and Ca2+ regulation of aquaporin water permeability. J. Gen. Physiol. 2004, 123, 573-580. [CrossRef] [PubMed].
57. Zelenina, M.; Bondar, A. A.; Zelenin, S.; Aperia, A. Nickel and extracellular acidification inhibit the water permeability of human aquaporin-3 in lung epithelial cells. J. Biol. Chem. 2003, 278, 30037-30043. [CrossRef] [PubMed].
58. Zelenina, M.; Tritto, S.; Bondar, A. A.; Zelenin, S.; Aperia, A. Copper inhibits the water and glycerol permeability of aquaporin-3. J. Biol. Chem. 2004, 279, 51939-51943. [CrossRef] [PubMed].
59. Tamás, M. J.; Karlgren, S.; Bill, R. M.; Hedfalk, K.; Allegri, L.; Ferreira, M.; Thevelein, J. M.; Rydström, J.; Mullins, J. G. L.; Hohmann, S. A short regulatory domain restricts glycerol transport through yeast Fps1p. J. Biol. Chem. 2003, 278, 6337-6345. [CrossRef] [PubMed].
60. Johansson, I.; Larsson, C.; Ek, B.; Kjellbom, P. The major integral proteins of spinach leaf plasma membranes are putative aquaporins and are phosphorylated in response to Ca2+ and apoplastic water potential. Plant. Cell 1996, 8, 1181-1191. [CrossRef] [PubMed].
61. Tournaire-Roux, C.; Sutka, M.; Javot, H.; Gout, E.; Gerbeau, P.; Luu, D.-T.; Bligny, R.; Maurel, C. Cytosolic pH regulates root water transport during anoxic stress through gating of aquaporins. Nature 2003, 425, 393-397. [CrossRef] [PubMed].
62. Zelenina, M.; Zelenin, S.; Bondar, A. A.; Brismar, H.; Aperia, A. Water permeability of aquaporin-4 is decreased by protein kinase C and dopamine. Am. J. Physiol. Ren. Physiol. 2002, 283, F309-F318. [CrossRef] [PubMed].
63. Gunnarson, E.; Zelenina, M.; Axehult, G.; Song, Y.; Bondar, A.; Krieger, P.; Brismar, H.; Zelenin, S.; Aperia, A. Identification of a molecular target for glutamate regulation of astrocyte water permeability. Glia 2008, 56, 587-596. [CrossRef] [PubMed].
64. Kitchen, P.; Conner, A. C. Control of the aquaporin-4 channel water permeability by structural dynamics of aromatic/arginine selectivity filter residues. Biochemistry 2015, 54, 6753-6755. [CrossRef] [PubMed].
65. Yu, J.; Yool, A. J.; Schulten, K.; Tajkhorshid, E. Mechanism of gating and ion conductivity of a possible tetrameric pore in aquaporin-1. Structure 2006, 14, 1411-1423. [CrossRef] [PubMed].
66. Nyblom, M.; Frick, A.; Wang, Y.; Ekvall, M.; Hallgren, K.; Hedfalk, K.; Neutze, R.; Tajkhorshid, E.; Törnroth-Horsefield, S. Structural and Functional Analysis of SoPIP2; 1 Mutants Adds Insight into Plant Aquaporin Gating. J. Mol. Biol. 2009, 387, 653-668. [CrossRef] [PubMed].
67. Janosi, L.; Ceccarelli, M. The gating mechanism of the human aquaporin 5 revealed by molecular dynamics simulations. PLoS ONE 2013, 8, e59897. [CrossRef] [PubMed].
68. Hashido, M.; Kidera, A.; Ikeguchi, M. Water transport in aquaporins: Osmotic permeability matrix analysis of molecular dynamics simulations. Biophys. J. 2007, 93, 373-385. [CrossRef] [PubMed].
69. Nicolotti, O.; Miscioscia, T. F.; Leonetti, F.; Muncipinto, G.; Carotti, A. Screening of matrix metalloproteinases available from the protein data bank: Insights into biological functions, domain organization, and zinc binding groups. J. Chem. Inf. Model. 2007, 47, 2439-2448. [CrossRef] [PubMed].
70. Zong, X.; Stieber, J.; Ludwig, A.; Hofmann, F.; Biel, M. A single histidine residue determines the pH sensitivity of the pacemaker channel HCN2. J. Biol. Chem. 2001, 276, 6313-6319. [CrossRef] [PubMed].
71. Sepúlveda, F. V.; Pablo Cid, L.; Teulon, J.; Niemeyer, M. I. Molecular aspects of structure, gating, and physiology of pH-sensitive background K2P and Kir K+-transport channels. Physiol. Rev. 2015, 95, 179-217. [CrossRef] [PubMed].
72. Thompson, A. N.; Posson, D. J.; Parsa, P. V.; Nimigean, C. M. Molecular mechanism of pH sensing in KcsA potassium channels. Proc. Natl. Acad. Sci. USA 2008, 105, 6900-6905. [CrossRef] [PubMed].
73. Kaptan, S.; Assentoft, M.; Schneider, H. P.; Fenton, R. A.; Deitmer, J. W.; MacAulay, N.; de Groot, B. L. H95 is a pH-dependent gate in aquaporin 4. Structures 2015, 23, 2309-2318. [CrossRef] [PubMed].
74. Krivobokova, T.; Briones, R.; Hub, J. S.; Munk, A.; de Groot, B. L. Partial least-squares functional mode analysis: Application to the membrane proteins AQP1, Aqy1, and CLC-ec1. Biophys. J. 2012, 103, 786-796. [CrossRef] [PubMed].
75. Henzler-Wildman, K.; Kern, D. Dynamic personalities of proteins. Nature 2007, 450, 964-972. [CrossRef] [PubMed].
76. Studer, R. A.; Dessailly, B. H.; Orengo, C. A. Residue mutations and their impact on protein structure and function: detecting beneficial and pathogenic changes. Biochem. J. 2013, 449, 581-594. [CrossRef] [PubMed].
77. Zimprich, A.; Benet-Pagès, A.; Struhal, W.; Graf, E.; Eck, S. H.; Offman, M. N.; Haubenberger, D.; Spielberger, S.; Schulte, E. C.; Lichtner, P.; et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am. J. Hum. Genet. 2011, 89, 168-175. [CrossRef] [PubMed].
78. Gsponer, J.; Ferrara, P.; Caflisch, A. Flexibility of the murine prion protein and its Asp178Asn mutant investigated by molecular dynamics simulations. J. Mol. Graph. Model. 2001, 20, 169-182. [CrossRef].
79. Shamsir, M. S.; Dalby, A. R. One gene, two diseases and three conformations: Molecular dynamics simulations of mutants of human prion protein at room temperature and elevated temperatures. Proteins Struct. Funct. Bioinform. 2005, 59, 275-290. [CrossRef] [PubMed].
80. Doss, C. G. P.; Rajith, B.; Garwasis, N.; Mathew, P. R.; Raju, A. S.; Apoorva, K.; William, D.; Sadhana, N. R.; Himani, T.; Dike, I. Screening of mutations affecting protein stability and dynamics of FGFR1-A simulation analysis. Appl. Transl. Genom. 2012, 1, 37-43. [CrossRef].
81. Elmore, D. E.; Dougherty, D. A. Molecular dynamics simulations of wild-type and mutant forms of the Mycobacterium tuberculosis MscL channel. Biophys. J. 2001, 81, 1345-1359. [CrossRef].
82. Pirolli, D.; Carelli Alinovi, C.; Capoluongo, E.; Satta, M. A.; Concolino, P.; Giardina, B.; de Rosa, M. C. Insight into a novel p53 single point mutation (G389E) by molecular dynamics simulations. Int. J. Mol. Sci. 2010, 12, 128-140. [CrossRef] [PubMed].
83. Imbrici, P.; Maggi, L.; Mangiatordi, G. F.; Dinardo, M. M.; Altamura, C.; Brugnoni, R.; Alberga, D.; Pinter, G. L.; Ricci, G.; Siciliano, G.; et al. ClC-1 mutations in myotonia congenita patients: insights into molecular gating mechanisms and genotype-phenotype correlation. J. Physiol. 2015, 593, 4181-4199. [CrossRef] [PubMed].
84. Horsten, U.; Müller-Newen, G.; Gerhartz, C.; Wollmer, A.; Wijdenes, J.; Heinrich, P. C.; Grötzinger, J. Molecular modeling-guided mutagenesis of the extracellular part of gp130 leads to the identification of contact sites in the interleukin-6 (IL-6)α IL-6 receptor gp130 Complex. J. Biol. Chem. 1997, 272, 23748-23757. [CrossRef] [PubMed].
85. De Graaf, C.; Oostenbrink, C.; Keizers, P. H.; van Vugt-Lussenburg, B. M.; van Waterschoot, R. A.; Tschirret-Guth, R. A.; Commandeur, J. N.; Vermeulen, N. P. Molecular modeling-guided site-directed mutagenesis of cytochrome P450 2D6. Curr. Drug Metab. 2007, 8, 59-77. [CrossRef] [PubMed].
86. Schushan, M.; Xiang, M.; Bogomiakov, P.; Padan, E.; Rao, R.; Ben-Tal, N. Model-guided mutagenesis drives functional studies of human NHA2, implicated in hypertension. J. Mol. Biol. 2010, 396, 1181-1196. [CrossRef] [PubMed].
87. Shyue, S.-K.; Ruan, K.-H.; Wang, L.-H.; Wu, K. K. Prostacyclin synthase active sites identification by molecular modeling-guided site-directed mutagenesis. J. Biol. Chem. 1997, 272, 3657-3662. [CrossRef] [PubMed].
88. Wang, L.-H.; Matijevic-Aleksic, N.; Hsu, P.-Y.; Ruan, K.-H.; Wu, K. K.; Kulmacz, R. J. Identification of thromboxane A2 synthase active site residues by molecular modeling-guided site-directed mutagenesis. J. Biol. Chem. 1996, 271, 19970-19975. [CrossRef] [PubMed].
89. Lucchinetti, C. F.; Mandler, R. N.; McGavern, D.; Bruck, W.; Gleich, G.; Ransohoff, R. M.; Trebst, C.; Weinshenker, B.; Wingerchuk, D.; Parisi, J. E.; et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002, 125, 1450-1461. [CrossRef] [PubMed].
90. Kira, J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: Astrocytopathy as a common denominator in demyelinating disorders. J. Neurol. Sci. 2011, 311, 69-77. [CrossRef] [PubMed].
91. Papadopoulos, M. C.; Verkman, A. S. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 2012, 11, 535-544. [CrossRef].
92. Pisani, F.; Mastrototaro, M.; Rossi, A.; Nicchia, G. P.; Tortorella, C.; Ruggieri, M.; Trojano, M.; Frigeri, A.; Svelto, M. Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. J. Biol. Chem. 2011, 286, 9216-9224. [CrossRef] [PubMed].
93. Rossi, A.; Baumgart, F.; van Hoek, A. N.; Verkman, A. S. Post-golgi supramolecular assembly of aquaporin-4 in orthogonal arrays. Traffic 2012, 13, 43-53. [CrossRef] [PubMed].
94. Nicchia, G. P.; Mastrototaro, M.; Rossi, A.; Pisani, F.; Tortorella, C.; Ruggieri, M.; Lia, A.; Trojano, M.; Frigeri, A.; Svelto, M. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 2009, 57, 1363-1373. [CrossRef] [PubMed].
95. Pisani, F.; Mola, M. G.; Simone, L.; Rosito, S.; Alberga, D.; Mangiatordi, G. F.; Lattanzi, G.; Nicolotti, O.; Frigeri, A.; Svelto, M.; et al. Identification of a point mutation impairing the binding between aquaporin-4 and neuromyelitis optica autoantibodies. J. Biol. Chem. 2014, 289, 30578-30589. [CrossRef] [PubMed].
96. Mangiatordi, G. F.; Alberga, D.; Siragusa, L.; Goracci, L.; Lattanzi, G.; Nicolotti, O. Challenging AQP4 druggability for NMO-IgG antibody binding using molecular dynamics and molecular interaction fields. Biochim. Biophys. Acta 2015, 1848, 1462-1471. [CrossRef] [PubMed].
97. Grossfield, A.; Zuckerman, D. M. Quantifying uncertainty and sampling quality in biomolecular simulations. Annu. Rep. Comput. Chem. 2009, 5, 23-48. [PubMed].
98. Keller, T. H.; Pichota, A.; Yin, Z. A practical view of 1druggability1. Curr. Opin. Chem. Biol. 2006, 10, 357-361. [CrossRef] [PubMed].
99. Verkman, A. S.; Anderson, M. O.; Papadopoulos, M. C. Aquaporins: Important but elusive drug targets. Nat. Rev. Drug Discov. 2014, 13, 259-277. [CrossRef] [PubMed].
100. Hughes, J.; Rees, S.; Kalindjian, S.; Philpott, K. Principles of early drug discovery. Br. J. Pharmacol. 2011, 162, 1239-1249. [CrossRef] [PubMed].
101. Schmidtke, P.; Barril, X. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. J. Med. Chem. 2010, 53, 5858-5867. [CrossRef] [PubMed].
102. Hussein, H. A.; Borrel, A.; Geneix, C.; Petitjean, M.; Regad, L.; Camproux, A.-C. PockDrug-Server: A new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res. 2015. [CrossRef] [PubMed].
103. Edfeldt, F. N. B.; Folmer, R. H. A.; Breeze, A. L. Fragment screening to predict druggability (ligandability) and lead discovery success. Drug Discov. Today 2011, 16, 284-287. [CrossRef] [PubMed].
104. Kandoi, G.; Acencio, M. L.; Lemke, N. Prediction of druggable proteins using machine learning and systems biology: A mini-review. Syst. Biol. 2015, 6, 366. [CrossRef] [PubMed].
105. Kozakov, D.; Hall, D. R.; Napoleon, R. L.; Yueh, C.; Whitty, A.; Vajda, S. New frontiers in druggability. J. Med. Chem. 2015, 58, 9063-9088. [CrossRef] [PubMed].
106. Cruciani, G.; Pastor, M.; Guba, W. VolSurf: A new tool for the pharmacokinetic optimization of lead compounds. Eur. J. Pharm. Sci. 2000, 11 (Suppl. S2), S29-S39. [CrossRef].
107. Henrich, S.; Salo-Ahen, O. M. H.; Huang, B.; Rippmann, F. F.; Cruciani, G.; Wade, R. C. Computational approaches to identifying and characterizing protein binding sites for ligand design. J. Mol. Recognit. 2010, 23, 209-219. [CrossRef] [PubMed].
108. Sirci, F.; Goracci, L.; Rodríguez, D.; van Muijlwijk-Koezen, J.; Gutiérrez-de-Terán, H.; Mannhold, R. Ligand-, structure-and pharmacophore-based molecular fingerprints: A case study on adenosine A1, A2A, A2B, and A3 receptor antagonists. J. Comput. Aided Mol. Des. 2012, 26, 1247-1266. [CrossRef] [PubMed].
109. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 1985, 28, 849-857. [CrossRef] [PubMed].
110. Cheng, A. C.; Coleman, R. G.; Smyth, K. T.; Cao, Q.; Soulard, P.; Caffrey, D. R.; Salzberg, A. C.; Huang, E. S. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 2007, 25, 71-75. [CrossRef] [PubMed].
111. Wolburg, H.; Wolburg-Buchholz, K.; Fallier-Becker, P.; Noell, S.; Mack, A. F. Structure and functions of aquaporin-4-based orthogonal arrays of particles. Int. Rev. Cell. Mol. Biol. 2011, 287, 1-41. [PubMed].
112. Crane, J. M.; Verkman, A. S. Reversible, temperature-dependent supramolecular assembly of aquaporin-4 orthogonal arrays in live cell membranes. Biophys. J. 2009, 97, 3010-3018. [CrossRef] [PubMed].
113. Liu, P.; Kim, B.; Friesner, R. A.; Berne, B. J. Replica exchange with solute tempering: A method for sampling biological systems in explicit water. Proc. Natl. Acad. Sci. USA 2005, 102, 13749-13754. [CrossRef] [PubMed].
114. Shoichet, B. K. Virtual screening of chemical libraries. Nature 2004, 432, 862-865. [CrossRef] [PubMed].
115. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: Methods and applications. Nat. Rev. Drug Discov. 2004, 3, 935-949. [CrossRef] [PubMed].
116. Ripphausen, P.; Nisius, B.; Bajorath, J. State-of-the-art in ligand-based virtual screening. Drug Discov. Today 2011, 16, 372-376. [CrossRef] [PubMed].
117. Ghosh, S.; Nie, A.; An, J.; Huang, Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol. 2006, 10, 194-202. [CrossRef] [PubMed].
118. Loving, K. A.; Lin, A.; Cheng, A. C. Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Comput. Biol. 2014, 10, e1003741. [CrossRef] [PubMed].
119. Koska, J.; Spassov, V. Z.; Maynard, A. J.; Yan, L.; Austin, N.; Flook, P. K.; Venkatachalam, C. M. Fully automated molecular mechanics based induced fit protein-ligand docking method. J. Chem. Inf. Model. 2008, 48, 1965-1973. [CrossRef] [PubMed].
120. Bolia, A.; Gerek, Z. N.; Ozkan, S. B. BP-Dock: A flexible docking scheme for exploring protein-ligand interactions based on unbound structures. J. Chem. Inf. Model. 2014, 54, 913-925. [CrossRef] [PubMed].
121. Oprea, T. I.; Bauman, J. E.; Bologa, C. G.; Buranda, T.; Chigaev, A.; Edwards, B. S.; Jarvik, J. W.; Gresham, H. D.; Haynes, M. K.; Hjelle, B.; et al. Drug repurposing from an academic perspective. Drug Discov. Today Ther. Strateg. 2011, 8, 61-69. [CrossRef] [PubMed].
122. Walker, S. L.; Waters, M. F. R.; Lockwood, D. N. J. The role of thalidomide in the management of erythema nodosum leprosum. Lepr. Rev. 2007, 78, 197-215. [PubMed].
123. Boolell, M.; Allen, M. J.; Ballard, S. A.; Gepi-Attee, S.; Muirhead, G. J.; Naylor, A. M.; Osterloh, I. H.; Gingell, C. Sildenafil: An orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 1996, 8, 47-52.
124. Tobinick, E. L. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009, 22, 119-125. [CrossRef] [PubMed].